NCT00402532View on ClinicalTrials.gov

Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation

PHASE3CompletedINTERVENTIONAL

Enrollment

190

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

November 30, 2011

Study Completion Date

December 31, 2011

Conditions

Lung Transplantation

Interventions

DRUG

Everolimus

Initial dosage 2 x 0.75 mg/d

DRUG

Mycophenolatmofetil

Initial dosage 2 x 500 mg/d intravenous

Trial Locations (1)

30625

Hannover Medical School, Division of Thoracic and Cardiovascular Surgery, Hanover

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Hannover Medical School

OTHER